### I. INTRODUCTION TO DYSTONIA

**Where we are now?**

- **08:20** Definition and classification of dystonia: How well is the 2013 Consensus Plan working
- **08:45** Dystonia syndromes: Overlapping or distinct?
- **09:10** What is the relationship between dystonia, Parkinson disease, essential tremor, and ataxia?
- **09:35** Current treatment for dystonia: What are the successes? What can we do better?

**Coffee Break**

**Late breaking news**

- **10:30** TBA (chosen from posters submitted)
- **10:35** TBA (chosen from posters submitted)
- **10:40** TBA (chosen from posters submitted)
- **10:45** TBA (chosen from posters submitted)

**Point and counterpoint: Dystonia and tremor**

- **10:50** Dystonia plus tremor = a discrete entity known as dystonic tremor
- **11:00** Dystonia plus tremor = two separate but frequently overlapping disorders

**Discussion**

**Hot topics: The science of phenotyping**

- **11:20** Pseudodystonia: Does it differ from “real” dystonia?
- **11:30** Paroxysmal dyskinesias: A subtype of dystonia or a different entity?

**Discussion**

**Chair’s summary & discussion with audience**

- **11:50** Chair’s summary of the morning session
- **12:00** Open discussion of morning session

**12:30** Lunch Break & Poster Session (provided for all delegates)

All posters viewable for entire meeting: 1st third to present today from 13:30-14:30

### II. SPECIAL TOPICS IN DYSTONIA

**Understanding mechanisms through the science of phenotyping**

- **14:30** Task-specific dystonia: What do they tell us about the etiology of dystonia?
- **14:50** Sex differences across the dystonias: How can we begin to delineate mechanisms?
- **15:10** Autoimmune mechanisms in dystonia: What can they tell us about the etiology of dystonia?
- **15:30** Dystonia in pediatrics: What can we learn from inherited metabolic disorders?

**Coffee Break**

**Point-counterpoint: Functional (psychogenic) dystonia.**

- **16:20** Functional dystonia: The biological basis of a neurological disorder
- **16:30** Functional dystonia: A pseudodystonia of psychiatric origin

**Discussion**

**Point-counterpoint: Non-motor features of dystonia**

- **16:50** Non-motor features of dystonia: Shared biological substrates for motor and non-motor feature
- **17:00** Non-motor features of dystonia: An expected side effect of a chronic disorder

**Discussion**

**Chair’s summary & discussion with audience**

- **17:20** Chair’s summary of the afternoon session
- **17:30** Open discussion of afternoon session

**19:00** WELCOME RECEPTION
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>Current concepts on integration of normal movement: cortex, basal ganglia and cerebellum</td>
</tr>
<tr>
<td>08:20</td>
<td>Structural imaging of human dystonia: Insights into cause or modern phrenology?</td>
</tr>
<tr>
<td>08:40</td>
<td>Functional imaging of human dystonia: Some common themes or too much heterogeneity?</td>
</tr>
<tr>
<td>09:00</td>
<td>Anatomical basis for dystonia: What can we learn from animal studies?</td>
</tr>
<tr>
<td>09:20</td>
<td>New imaging methods: How can they be applied in dystonia?</td>
</tr>
<tr>
<td>10:00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>10:30</td>
<td>TBA (chosen from posters submitted)</td>
</tr>
<tr>
<td>10:40</td>
<td>TBA (chosen from posters submitted)</td>
</tr>
<tr>
<td>10:45</td>
<td>TBA (chosen from posters submitted)</td>
</tr>
<tr>
<td>11:20</td>
<td>Cervical dystonia is caused by a defect in the neural integrator for head control</td>
</tr>
<tr>
<td>11:30</td>
<td>Cervical dystonia is caused by a defect in the network for attentional orienting</td>
</tr>
<tr>
<td>11:40</td>
<td>Discussion</td>
</tr>
<tr>
<td>11:50</td>
<td>Chair’s summary of the morning session</td>
</tr>
<tr>
<td>12:00</td>
<td>Open discussion of morning session</td>
</tr>
<tr>
<td>12:30</td>
<td>Lunch Break &amp; Poster Session (provided for all delegates)</td>
</tr>
<tr>
<td>13:30</td>
<td>All posters viewable for entire meeting: 2nd third to present today from 13:30-14:30</td>
</tr>
<tr>
<td>14:30</td>
<td>Physiological changes in human dystonia: Where are we now?</td>
</tr>
<tr>
<td>14:50</td>
<td>Deep brain stimulation in humans: What can we learn about etiology?</td>
</tr>
<tr>
<td>15:10</td>
<td>Does dystonia begin in the basal ganglia?</td>
</tr>
<tr>
<td>15:30</td>
<td>Does dystonia begin in the cerebellum?</td>
</tr>
<tr>
<td>15:50</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>16:20</td>
<td>Abnormal sensory processes are a fundamental defect underlying dystonia</td>
</tr>
<tr>
<td>16:30</td>
<td>Abnormal sensory processes are a non-specific consequence of the disorder</td>
</tr>
<tr>
<td>16:40</td>
<td>Discussion</td>
</tr>
<tr>
<td>16:50</td>
<td>Abnormal plasticity is the fundamental defect underlying dystonia</td>
</tr>
<tr>
<td>17:00</td>
<td>Abnormal plasticity is a non-specific consequence of many movement disorders</td>
</tr>
<tr>
<td>17:10</td>
<td>Discussion</td>
</tr>
<tr>
<td>17:20</td>
<td>Chair’s summary</td>
</tr>
<tr>
<td>17:30</td>
<td>Open discussion of afternoon session</td>
</tr>
</tbody>
</table>
Day 3: Saturday, 6 June 2020

V. MOLECULAR MECHANISMS

Dystonia genes: A growing list
08:00 Overview of dystonia genetics
08:20 Dystonias with partial penetrance: What are the biological mechanisms?
08:40 Induced pluripotent stem cells: Novel technologies and application to dystonia
09:00 Shared biological pathways in dystonia: One or many paths to novel therapeutics?
09:20 Research resources: What is available?

10:00 Coffee Break

10:30 TBA (chosen from posters submitted)
10:40 TBA (chosen from posters submitted)
10:45 TBA (chosen from posters submitted)

Point and counterpoint: New gene nomenclature for dystonia
10:50 The value of the new gene nomenclature for dystonia
11:00 We do not need new names for old genes
11:10 Discussion

Point and counterpoint: Rare monogenic dystonias vs common idiopathic dystonias
11:20 Results from monogenic dystonias provide novel insights for common idiopathic dystonia
11:30 Results from monogenic dystonias are not relevant to more common idiopathic dystonias
11:40 Discussion

Chair’s summary & discussion with the audience
11:50 Chairs summary
12:00 Open discussion of morning session

12:30 Lunch Break & Poster Session (lunch provided for all delegates)
All posters viewable for entire meeting: 3rd third to present today from 13:00-14:00

VI. EXPERIMENTAL THERAPEUTICS

Novel therapeutics on the horizon
14:30 Novel experimental oral therapeutics: What are the targets?
14:50 Botulinum toxin therapy: What are the new trends?
15:10 Surgical therapies: What’s next?
15:30 Clinical trials: What are the obstacles to testing new options?
15:50 Coffee Break

Hot topics: Some recent successes
16:20 Physical and occupational therapy in dystonia:
16:40 Inherited dystonias with targeted therapies
17:00 PKAN: One enzyme defect, multiple targets

Chair’s summary & audience discussion
17:20 Chairs summary of the session
17:30 Audience Discussion

18:00 CONFERENCE CONCLUDES